Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/402—1-aryl substituted, e.g. piretanide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Definitions

• the invention relates to the use of benzoylguanidines of the formula I
• R 1 is A
• R 2 is Het, CnFmH mOp, R 4 , OR 4 , OH, benzyl, CN, Hal, SO q -R 5 ,
• Ph, O-Ph, O-Het, NH-Het, NH 2 , NHA, NA 2 or NH-Ph, R 3 is S0 2 A,
• R 4 is a straight-chain or branched alkyl radical having 1 to 8 C atoms or cycloalkyl having 3 to 8 C atoms which can be unsubstituted or mono-, di- or trisubstituted by A
• R 5 is A or Ph
• A, A' in each case independently of one another are alkyl having 1 to
• Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having from 1 to 4 N, O and/or S atoms, which can be substituted once, twice or three times by Hal, CF 3 , A, CN, N0 2 , NH 2 and/or carbonyl oxygen, Hal is F, Cl, Br o l,
• Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF 3 , NH 2 , NHA or NA 2 , m is 1 , 2, 3, 4, 5, 6, 7, but at most 2n+1 , n is 1 , 2 or 3, p is 0 or 1 , q is 0, 1 or 2, and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus. and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus.
• the compounds of formula I are known from EP 0 699 666, EP 0 699 663, EP 0 743 301 , EP 0 704431 , EP 0 758 644, EP 0 699 660, EP 0 725 062, EP 0 708 088, EP 0 694 537 and EP 0723 963. They are potent inhibitors of the cellular sodium-proton-antiporter (Na + /H + -exchanger).
• Benzoylguanidines with other substitution patterns are discribed e.g. in EP 0 589 336 as inhibitors of the cellular sodium-proton-antiporter, which shows an increased level in diabetes.
• pyrazinoylguanidines for the treatment of diabetes mellitus is disclosed in WO 97/21438.
• the invention was based on the object of finding compounds having useful properties, in particular those which can be used for the production of medicaments.
• NIDDM non-insulin-dependent diabetes mellitus
• the compounds of the formula I and their salts can be used for the production of a medicament for lowering and/or controlling the blood sugar levels of NIDDM persons. Additionally, the compounds of the formula I and their salts can be used for the production of a medicament for lowering and/or controlling the levels of insulin, free fatty acids and triglycerides of NIDDM persons.
• the invention thus relates to the use of benzoylguanidines of the formula I wherein the compounds are selected from the group
• Solvates means addition compounds with e.g. water or alcoholes.
• Alkyl has 1 to 6, preferably 1 , 2, 3, 4, 5 or 6 C atoms.
• Alkyl is therefore in particular, for example, methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyl,
• R preferably means alkyl having 1-6 C atoms, preferably e.g. methyl, ethyl, propyl or isopropyl, most preferably methyl.
• R 3 means S0 2 A', wherein A preferably is e.g. methyl, ethyl, propyl, isopropyl or butyl, most preferably R 3 means SO 2 CH 3 .
• Het is preferably 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyi, furthermore preferably 1 ,2,3-triazol-1-, -4- or -5- yl, 1 ,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1 ,2,3-oxadiazol-4- or -5-yl, 1 ,2,4-oxadiazol-3- or 5-yl, 1 ,3,4-thiadiazol-2- or -5-yl, 1 ,2,4-thiadiazol-3- or -5-yl,
• 6- or 7-benzothiazolyl 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7- be ⁇ zo-2,1 ,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-,
• heterocyclic radicals can also be partially or completely hydrogenated.
• Het can thus, for example, also be 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1 ,3- dioxoian-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5- pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidi ⁇ yl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5- pyrazolyl, tetrahydro-1-, -3- or -4-pyrazoly
• Het means 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1- pyrrolidinyl, 1-pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl; the most preferred meaning is 1-pyrrolyl.
• o C n F m H 2n+ ⁇ -mOp is preferably OCF 3 , OCH 2 F, OCHF 2 , CF 3 C 2 F 5 or partially fluorinated alkyl having 1-4 C atoms, CH 2 F, CHF 2 , C 2 HF 4 , C 2 H 2 F 3 or C 2 H 4 F.
• R 4 is preferably a straight-chain or branched alkyl radical having 1 to 8 C
• R is noncyclic, the radical is then, preferably, one of the alkyl radicals which are also preferred for A.
• Particularly preferred cycloalkyl radicals which can be R 4 are cyclopropyi, cyclobutyl, cyclopentyl or cyclohexyl, or their derivatives which are 20 substituted once by A, in particular methyl, ethyl or isopropyl.
• R 2 is preferably e.g. F, Cl, Br, methyl, ethyl, propyl, iso-propyl, 2-butyl, -(CH 2 ) 4 -CH 3 , cyclobutyl, cyclohexyl, p-tolyl, 4-chlorophenyl, 2,4-dichloro- phenyl, 4-fluorophenyl, 3,5-bis(trifluoromethyl)phenyl, 3,5-dichlorophenyl,
• the invention relates in particular to the use of those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
• Some preferred groups of compounds can be expressed by the following subformulae la to 1i, which correspond to the formula I and in which the radicals not ⁇ Q described in greater detail have the meaning indicated in the formula I, but in which
• R 3 is S0 2 CH 3 ;
• R 3 is S0 2 CH 3 ;
• R 3 is S0 2 CH 3 ;
• R 2 is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidinyl, 1- pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl;
• R 1 is methyl or ethyl
• R J is SO 2 A *
• R 4 is a straight-chain or branched alkyl radical having 1 to 6 C atoms or cycloalkyl having 3 to 6 C atoms which can be unsubstituted or monosubstituted by A
• R 5 is A or Ph
• A' is alkyl having 1 to 6 C atoms
• Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having from 1 to 4 N, O and/or S atoms, which can be substituted once, twice or three times by Hal, CF 3 , A, CN, N0 2 , NH 2 and/or carbonyl oxygen,
• Hal isF, Cl, Brorl, Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF 3 , NH 2 , NHA or NA 2 , m is 1, 2, 3, 4, 5, 6, 7, but at most 2n+1, n is 1,2 or 3, p isOorl; q is 0 or 2;
• R 1 is methyl or ethyl, R 3 is S0 2 CH 3 ;
• R 2 is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidinyi, 1- pyrrolyl, pyridyl, oxodihydropyridyl, benzimidazolyl, C n FmH 2 n+ ⁇ -mOp or R ;
• R 4 is a straight-chain or branched alkyl radical having 1 to 6 C atoms or cycloalkyl having 3 to 6 C atoms which can be unsubstituted or monosubstituted by A, A is alkyl having 1 to 6 C atoms, m is 1,2,3,4, 5,6, 7, but at most 2n+1, n is 1,2 or 3, p isOorl;
• R 1 is methyl or ethyl, R 3 is S0 2 CH 3 ;
• R 2 is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidi ⁇ yl, 1- pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl, CF 3 , OCF 3 or alkyl having 1 to 6 C atoms;
• R 3 is S0 2 CH 3 ;
• R 2 is 1-pyrrolyl, CF 3 , OCF 3 or alkyl having 1 to 4 C atoms
• R 3 is S0 2 A
• R 2 is Het, R 4 , OR 4 , OH, benzyl, CN, F, Cl,
• R ⁇ 4 is a straight-chain or branched alkyl radical having 1 to 6 C atoms or cycloalkyl having 3 to 6 C atoms which can be unsubstituted or monosubstituted by A, R 5 is A or Ph,
• A, A' is alkyl having 1 to 6 C atoms
• Het is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidinyi, 1- pyrrolyl, pyridyl, oxodihydropyridyl, benzimidazolyl, which can be substituted once, twice or three times by Hal, CF 3 , A, CN, N0 2 , NH 2 and/or carbonyl oxygen, Hal is F, Cl, Br or l, Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF 3 , NH 2 , NHA or NA 2 , m is 1 , 2, 3, 4, 5, 6, 7, but at most 2n+1 , n is 1 , 2 or 3, p is 0 or 1 ; q is 0 or 2; and/or their physiologically acceptable salts and solvates.
• the compounds of formula I can be used in the form of salts derived from inorganic or organic acids or bases.
• a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation.
• possible acids are in particular those which yield physiologically acceptable salts.
• inorganic acids can be used, e.g.
• sulfuric acid nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, further organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocydic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
• compounds of the formula I can be converted using bases (e.g. sodium or potassium hydroxide or carbonate) into the corresponding metal salts, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts.
• bases e.g. sodium or potassium hydroxide or carbonate
• test results of the antidiabetic activity of some representative compounds of the formula I are compiled in Table I which follows.
• the compounds were administered by oral route on an animal model of diabetes (NOSTZ rats) showing a moderate diabetic state.
• the compounds were studied using the procedure that is: determination of basal glycemia, lactatemia and insulinemia before treatment day 0, 2 hours after acute (day 1) and 2 hours after the last administration of the chronic treatment (once a day during 4 days) of the compounds at 20 mg/kg.
• the pharmacological data confirm that the tested compounds at 20 mg/kg decreased significantly the fasting plasma glucose after acute and chronic treatment.
• the invention further relates to the use of the compounds of the formula I and/or their physiologically acceptable salts for the production of pharmaceutical preparations for the treatment of non-insulin-dependent diabetes mellitus, in particular in a non-chemical way.
• they can be brought into a suitable dose form together with at least one solid, liquid and/or semiliquid excipient or auxiliary and if appropriate in combination with one or more of the further active compounds.
• the invention further relates to a pharmaceutical preparation for the treatment of non-insulin-dependent diabetes mellitus containing at least one compound of the formula I and/or one of its physiologically acceptable salts or solvates.
• the invention further relates to a pharmaceutical preparation for the treatment of non-insulin-dependent diabetes mellitus, characterized in that it contains at least one compound selected from the group a) N-diaminomethylene-2-methyl-4-(1-pyrrolyl)-5-methylsulfonyl- enzamide, b) N-diaminomethyle ⁇ e-2-methyl-4-trifluoromethyl-5-methylsulfonyl- benzamide, c) N-diaminomethylene-2-methyl-4-isopropyl-5-methylsulfony- benzamide, and/or one of its physiologically salts or solvates.
• a pharmaceutical preparation for the treatment of non-insulin-dependent diabetes mellitus characterized in that it contains at least one compound selected from the group a) N-diaminomethylene-2-methyl-4-(1-pyrrolyl)-5-methylsulfonyl- enzamide, b) N-diaminomethyle ⁇ e-2-methyl
• preparations can be used as medicaments in human or veterinary medicine.
• Possible excipients are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc and petroleum jelly.
• Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used in particular for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, and in addition suspensions, emulsions or implants are used for parentaral administration, and ointments, creams or powders are used for topical application.
• the compounds of formula I can aiso be lyophiiized and the lyophilizates obtained used, for example, for the production of injection preparations.
• the preparations indicated can be sterilized and/or can contain auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more further active compounds, e.g. one or more vitamins.
• auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more further active compounds, e.g. one or more vitamins.
• the compounds of formula I according to the invention are generally administered in analogy to other known commercially available preparations for the indications claimed (e.g. metformine or amiioride), preferably in doses of between 0.1 mg and 500 mg, in particular between 5 and 300 mg per dose unit.
• the daily dose is preferably between approximately 0.01 and 250 mg/kg, in particular between 0.02 and 100 mg/kg of body weight.
• the substances according to the formula I are generally preferably administered in doses of between approximately 1 and 500 mg, in particular between 5 and 100 mg per dose unit.
• the daily dose is preferably between approximately 0.02 and 10 mg/kg of body weight.
• the specific dose for each patient depends on all sorts of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy relates. Oral administration is preferred.
• a solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 I of double-distilled water using 2 N hydrochloric acid, sterile-filtered, filled into injection vials and lyophilized under sterile conditions, and the vials are aseptically sealed. Each injection vial contains 5 mg of active compound.
• a mixture of 20 g of an active compound of the formula I is fused with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.
• a solution is prepared from 1 g of an active compound of the formula I, 9.38 g of NaH 2 P0 4 .2H 2 0, 28.48 g of Na 2 HP0 4 .12H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of double-distilled water. The pH is adjusted to 6.8, and the solution is made up to 1 I and sterilized by irradiation.
• 500 mg of an active compound of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
• Example F Coated tablets
• Example E tablets are pressed which are then coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth and colourant.
• a solution of 1 kg of active compound of the formula I in 60 i of double- distilled water is steriie- filtered, filled into ampoules and lyophilized under sterile conditions, and the ampoules are aseptically sealed. Each ampoule contains 10 mg of active compound.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Diabetes (AREA)
• Epidemiology (AREA)
• Endocrinology (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Emergency Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pyrrole Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=8233036

Family Applications (1)

Country Status (14)

Families Citing this family (3)

Family Cites Families (7)

• 1999
  • 1999-11-16 WO PCT/EP1999/008795 patent/WO2000030624A2/en not_active Application Discontinuation
  • 1999-11-16 CA CA002352154A patent/CA2352154A1/en not_active Abandoned
  • 1999-11-16 JP JP2000583507A patent/JP2002530325A/ja active Pending
  • 1999-11-16 KR KR1020017006615A patent/KR20010080597A/ko not_active Application Discontinuation
  • 1999-11-16 PL PL99348152A patent/PL348152A1/xx unknown
  • 1999-11-16 EP EP99958047A patent/EP1131064A2/de not_active Ceased
  • 1999-11-16 CN CN99813826A patent/CN1328452A/zh active Pending
  • 1999-11-16 ID IDW00200101318A patent/ID29523A/id unknown
  • 1999-11-16 CZ CZ20011785A patent/CZ20011785A3/cs unknown
  • 1999-11-16 AU AU15535/00A patent/AU1553500A/en not_active Abandoned
  • 1999-11-16 HU HU0104418A patent/HUP0104418A2/hu unknown
  • 1999-11-16 BR BR9915667-9A patent/BR9915667A/pt not_active Application Discontinuation
  • 1999-11-26 AR ARP990106043A patent/AR023064A1/es unknown
• 2001
  • 2001-05-25 NO NO20012563A patent/NO20012563D0/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events